Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MapLight Therapeutics, Inc. - Common Stock (NQ:MPLT)

26.43 -2.30 (-8.02%)
Streaming Delayed Price Updated: 3:58 PM EDT, May 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 481,151
Open 28.20
Bid (Size) 26.34 (1,500)
Ask (Size) 26.51 (1,600)
Prev. Close 28.73
Today's Range 25.21 - 28.21
52wk Range 12.24 - 33.28
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold? ↗
This clinical-stage biotech focused on CNS disorders reported a notable insider sale amid ongoing development of its neurology pipeline. 
Via The Motley Fool
Topics Derivatives Regulatory Compliance
News headline image
MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
From MapLight Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+57.6%
+57.6%
1 Month
-12.1%
-12.1%
3 Month
+53.2%
+53.2%
6 Month
+93.0%
+93.0%
1 Year
+44.1%
+44.1%

More News

Read More
News headline image
MapLight Therapeutics to Participate in Upcoming Investor Conferences
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
This MapLight Insider Sold 69,000 Shares for $2.1 Million at the End of April ↗
Via The Motley Fool
Topics Derivatives Regulatory Compliance
News headline image
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics to Participate in Upcoming Investor Conferences
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From MapLight Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is MapLight Therapeutics, Inc. - Common Stock publicly traded?
Yes, MapLight Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does MapLight Therapeutics, Inc. - Common Stock trade on?
MapLight Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MapLight Therapeutics, Inc. - Common Stock?
The ticker symbol for MapLight Therapeutics, Inc. - Common Stock is MPLT on the Nasdaq Stock Market
What is the current price of MapLight Therapeutics, Inc. - Common Stock?
The current price of MapLight Therapeutics, Inc. - Common Stock is 26.43
When was MapLight Therapeutics, Inc. - Common Stock last traded?
The last trade of MapLight Therapeutics, Inc. - Common Stock was at 05/18/26 03:58 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.